ORIC Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, ORIC Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $21.71. The average 1-year stock price forecast is 139.36% higher than the current stock price, while the lowest is $14 (+54.36%) and the highest is $27 (+197.68%).

Price Target: $21.71 (+139.36%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$14	$21.71	$23.5	$27
Change	+54.36%	+139.36%	+159.10%	+197.68%

Analyst Ratings

The average analyst rating for ORIC Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	13	13	12	11	12	12
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	15	14	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Boris Peaker JonesTrading	JonesTrading	Buy Reiterates $25	Buy	Reiterates	$25	+175.63%	Oct 27, 2026
Prakhar Agrawal Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Oct 27, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $27	Buy	Reiterates	$27	+197.68%	Oct 27, 2026
Unknown Analyst Wedbush No rating	Wedbush	Buy Maintains $17 → $14	Buy	Maintains	$17 → $14	+54.36%	Oct 27, 2026
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $14 → $18	Buy	Maintains	$14 → $18	+98.46%	Oct 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.49

from -1.47

EPS Next Year

-1.69

from -1.49

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-78.87M	-86.77M	-110.78M	-142.90M	-143.00M	-178.97M
Net Income	-78.72M	-89.12M	-100.70M	-127.85M	-129.47M	-166.02M
EPS	-	-	-	-	-1.47	-1.49
Free Cash Flow	-	-	-	-	-111.68M	-134.50M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.25
Avg	-1.49
Low	-1.64

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-